Skip to content

Ketamine: all studies

Page 121 of 449: studies 1,201 to 1,210 of 4,486, newest first. Back to the ketamine overview

Research

Sex difference alters the behavioral and cognitive performance in a rat model of schizophrenia induced by sub-chronic ketamine.

Journal of Psychiatric Research October 1, 2024 Mohammad-Ali Samizadeh, Seyedeh-Tabassom Abdollahi-Keyvani, Hamed Fallah et al. 21 citations

Schizophrenia is a complex neuropsychiatric disorder with positive, negative, and cognitive symptoms. In rats, sub-chronic administration of ketamine is used for the induction of schizophrenia model. Increased locomotor activity is one of the most important features of psychotic-like symptoms in rodents. On the other hand, risperidone is a potent antipsychotic medication that is approved for...

Fast-acting antidepressant-like effects of ketamine in aged male rats.

Pharmacological Reports October 1, 2024 Elena Hernández-Hernández, Sandra Ledesma-Corvi, Jordi Jornet-Plaza et al. 8 citations

The aging process causes anatomical and physiological changes that predispose to the development of late-life depression while reduces the efficacy of classical antidepressants. Novel fast-acting antidepressants such as ketamine might be good candidates to be explored in the context of aging, especially given the lack of previous research on its efficacy for this age period. Thus, the aim of...

DOI: 10.1007/s43440-024-00636-y (opens in new tab) Full text (opens in new tab) Aging Bdnf Fast-acting antidepressant Ketamine therapy +4

Ketamine alleviates PTSD-like effect and improves hippocampal synaptic plasticity via regulation of GSK-3β/GR signaling of rats.

Journal of Psychiatric Research October 1, 2024 Zixun Wang, Xinyu Hu, Zhongyi Wang et al. 9 citations

Each year, 3-4% of the global population experiences post-traumatic stress disorder (PTSD), a chronic mental disorder with significant social and economic repercussions. Although it has been shown that ketamine can effectively alleviate PTSD symptoms in individuals, the specific mechanism of action underlying its anti-PTSD effects remains unclear. In this study, we investigated how a single,...

GluN2B on Adult-Born Granule Cells Modulates (R,S)-Ketamine's Rapid-Acting Effects in Mice.

The International Journal of Neuropsychopharmacology October 1, 2024 Nicholas E Bulthuis, Josephine C McGowan, Liliana R Ladner et al. 2 citations

Standard antidepressant treatments often take weeks to reach efficacy and are ineffective for many patients. (R,S)-ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has been shown to be a rapid-acting antidepressant and to decrease depressive symptoms within hours of administration. While previous studies have shown the importance of the GluN2B subunit of the NMDA receptor on...

Ketamine Prevents Inflammation-Induced Reduction of Human Hippocampal Neurogenesis via Inhibiting the Production of Neurotoxic Metabolites of the Kynurenine Pathway.

The International Journal of Neuropsychopharmacology October 1, 2024 Gargi Mandal, Madeline Kirkpatrick, Silvia Alboni et al. 12 citations

Understanding the precise mechanisms of ketamine is crucial for replicating its rapid antidepressant effects without inducing psychomimetic changes. Here, we explore whether the antidepressant-like effects of ketamine enantiomers are underscored by protection against cytokine-induced reductions in hippocampal neurogenesis and activation of the neurotoxic kynurenine pathway in our...

DOI: 10.1093/ijnp/pyae041 (opens in new tab) Full text (opens in new tab) Cytokines Apoptosis Hippocampal neurogenesis Kynurenine pathway +3

Intravenous ketamine successfully treats treatment-resistant catatonia in schizophrenia: A case report.

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy October 1, 2024 Atif Siddiqui 5 citations

Benzodiazepines and electroconvulsive therapy (ECT) are mainstay treatments for catatonia, a potentially life-threatening psychomotor syndrome characterized by a range of symptoms, including immobility, mutism, stupor, posturing, and sometimes even agitation. It can be a manifestation of various underlying psychiatric or medical conditions, such as schizophrenia, mood disorders, or neurological...

DOI: 10.1002/phar.4612 (opens in new tab) Full text (opens in new tab) Catatonia treatment Ketamine therapy Geriatric psychiatry Schizophrenia management +1

Ketamine Impact on Kidney Health.

Cureus October 1, 2024 Sana Rahman, Samiya Saher, Anurag Raje et al.

Ketamine-induced uropathy (KIU) is a serious consequence of chronic ketamine abuse, presenting with complex renal and urinary symptoms. This study describes a 34-year-old female with a history of chronic ketamine abuse, resulting in stage 3 chronic kidney disease (CKD) and severe urological complications. Despite discontinuing ketamine use five years ago, she remains dependent on ureteral...

DOI: 10.7759/cureus.70804 (opens in new tab) Full text (opens in new tab) Bilateral hydronephrosis Burning micturition Dysuria Flank pain +10

The Effectiveness of Ketamine Treatment on Depression

Communications in Humanities Research September 27, 2024 Yichen Liu

As the diagnosis rate of depression continues to rise, effective treatment options for this condition have become one of the most researched areas in the field. Earlier antidepressants were primarily developed based on mechanisms that involve regulating imbalanced neurotransmitters. For example, the widely known Selective Serotonin Reuptake Inhibitors (SSRIs) and various tricyclic...

The impact of ketamine on emergency rapid sequence intubation: a systematic review and meta-analysis.

BMC emergency medicine September 27, 2024 Qinxue Hu, Xing Liu, Tao Xu et al. 3 citations

Rapid sequence intubation (RSI) is a crucial step in the resuscitation process for critically ill patients, and the judicious use of sedative drugs during RSI significantly influences the clinical outcomes of patients. Ketamine is a commonly used anesthetic sedative; however, its impact on the mortality of patients undergoing RSI has yielded inconsistent findings. Therefore, we conducted a...

Ketamine and Psilocybin Differentially Impact Sensory LearningDuring the Mismatch Negativity

Research Square September 26, 2024 Shona G. Allohverdi, Milad Soltanzadeh, André Schmidt et al. preprint

Abstract Ketamine and psilocybin show potential as therapies for various mental illnesses, including major depressive disorder. However, further investigation into their neural mechanisms is required to understand their effects on the brain. By combining computational modelling with electroencephalography (EEG), we examine the effects of ketamine and psilocybin on hierarchical sensory...